Comparison of eravacycline and cefiderocol in the treatment of multidrug-resistant Acinetobacter baumannii infections

A. baumannii is a common cause of drug-resistant hospital-associated infections. Eravacycline and cefiderocol are two recently introduced antibiotics that have demonstrated in vitro activity against drug-resistant A. baumannii , but data regarding the clinical utility of these drugs against multi-drug resistant A. baumannii infections (MDRAI) is lacking. In this study, we performed a retrospective chart review of patients with MDRAI who were treated with cefiderocol or eravacycline to compare clinical outcomes associated with each antibiotic. 40 patients were included, of which 30 patients received cefiderocol, 9 received eravacycline, and 1 received both. We collected data on demographics, risk factors for MDRAI, and infection characteristics. The primary outcomes assessed were hospital mortality rates. Secondary outcomes assessed were readmission rates, ICU admission, shock requiring vasopressors, mechanical intubation, and drug-related adverse events. No significant differences in the primary outcomes of 30-day and 90-day mortality rates were observed between the two groups.